Literature DB >> 6843661

Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene.

A Balmain, I B Pragnell.   

Abstract

Several groups have shown that the malignant phenotype can be transferred to NIH/3T3 fibroblasts by incorporation of DNA isolated from tumour cell lines. These studies have demonstrated that the transforming activity of DNA isolated from human bladder, lung and colon carcinoma cell lines is related to an alteration of the cellular homologues of the ras genes of Harvey or Kirsten murine sarcoma viruses. It is, however, unclear what relevance these observations have to the multi-stage nature of tumorigenesis in vivo, in which several independent events are required in both humans and experimental animals. The activation of a cellular oncogene in a defined experimental system for the progressive induction of solid tumours has not yet been demonstrated. We report here that high molecular weight DNA from transplanted squamous cell carcinomas induced by sequential treatment of mouse skin with initiators and promoters of carcinogenesis causes morphological transformation of NIH/3T3 fibroblasts at high frequency. The transforming properties are due to the transfer of an activated cellular homologue of the Harvey-ras (rasH) oncogene.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6843661     DOI: 10.1038/303072a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  110 in total

Review 1.  IκB kinase alpha and cancer.

Authors:  Shuang Liu; Zhisong Chen; Feng Zhu; Yinling Hu
Journal:  J Interferon Cytokine Res       Date:  2011-12-07       Impact factor: 2.607

2.  K-Ras and mitochondria: dangerous liaisons.

Authors:  Jiri Neuzil; Jakub Rohlena; Lan-Feng Dong
Journal:  Cell Res       Date:  2011-09-27       Impact factor: 25.617

3.  Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression.

Authors:  K Brown; A Buchmann; A Balmain
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

Review 4.  Role of IKKα in skin squamous cell carcinomas.

Authors:  Eunmi Park; Bigang Liu; Xiaojun Xia; Feng Zhu; Willette-Brown Jami; Yinling Hu
Journal:  Future Oncol       Date:  2011-01       Impact factor: 3.404

Review 5.  Modulation of protein kinase signaling cascades by palytoxin.

Authors:  Elizabeth V Wattenberg
Journal:  Toxicon       Date:  2010-11-09       Impact factor: 3.033

6.  Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation.

Authors:  Marcelo L Rodriguez-Puebla; Paula L Miliani de Marval; Margaret LaCava; David S Moons; Hiroaki Kiyokawa; Claudio J Conti
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

7.  Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions.

Authors:  Panomwat Amornphimoltham; Kantima Leelahavanichkul; Alfredo Molinolo; Vyomesh Patel; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2008-12-10       Impact factor: 12.531

8.  Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion.

Authors:  A B Glick; A B Kulkarni; T Tennenbaum; H Hennings; K C Flanders; M O'Reilly; M B Sporn; S Karlsson; S H Yuspa
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

9.  Invasive melanoma in Cdk4-targeted mice.

Authors:  R Sotillo; J F García; S Ortega; J Martin; P Dubus; M Barbacid; M Malumbres
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

10.  Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.

Authors:  Karin List; Roman Szabo; Alfredo Molinolo; Virote Sriuranpong; Vivien Redeye; Tricia Murdock; Beth Burke; Boye S Nielsen; J Silvio Gutkind; Thomas H Bugge
Journal:  Genes Dev       Date:  2005-08-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.